Clinical Trial Update: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC [Phase 3]

View source ↗

Summary

Phase 3 trial update for PM8002 or placebo plus Nab-Paclitaxel as first-line therapy in inoperable locally advanced or metastatic triple-negative breast cancer,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• PM8002

Snippet

Sponsor: Biotheus Inc. | Conditions: Triple Negative Breast Cancer(TNBC) | Phase 3 | Status: RECRUITING